Enrico Pedemonte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10193937/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	1.4	1,318
2	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology, 2007, 61, 219-227.	5.3	450
3	Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	163
4	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	3.3	159
5	α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	2.3	118
6	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics, 2007, 8, 65.	2.8	61
7	Migraineurs show a high prevalence of antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 2011, 9, 1350-1354.	3.8	35
8	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. , 2006, 111, 555-566.		30
9	Biological markers of the inflammatory phase of multiple sclerosis. Neurological Sciences, 2003, 24, s271-s274.	1.9	24
10	Anatomical Variants of the Circle of Willis and Brain Lesions in Migraineurs. Canadian Journal of Neurological Sciences, 2011, 38, 494-499.	0.5	19
11	Parkinsonism in multiple sclerosis patients: A casual or causal association?. Parkinsonism and Related Disorders, 2013, 19, 492-493.	2.2	13
12	Sneddon's syndrome presenting with severe disabling bilateral headache. Journal of Headache and Pain, 2009, 10, 211-213.	6.0	9
13	OR.82. Mesenchymal Stem Cells Treat CNS Autoimmunity Through a Dual Effect On Inflammation and Tissue Damage. Clinical Immunology, 2006, 119, S35.	3.2	Ο